Warrawee, Australia

Philip Anthony Jennings

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Macquarie Park, AU (2014)
  • Warrawee, AU (2010 - 2020)

Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovations of Philip Anthony Jennings

Introduction

Philip Anthony Jennings is a notable inventor based in Warrawee, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for treating gastrointestinal and lung diseases. With a total of 8 patents to his name, Jennings continues to push the boundaries of medical science.

Latest Patents

Among his latest patents are groundbreaking inventions related to antibodies that specifically bind to TNF-like ligand 1a (TL1a). One of his patents discloses TL1a-binding proteins that comprise an antigen binding domain of an antibody, which binds specifically to TL1a and inhibits the interaction of TL1a with Death Receptor 3 (DR3). Importantly, these proteins do not inhibit the interaction of TL1a with Decoy Receptor 3 (DcR3). The disclosure also outlines various uses for these TL1a-binding proteins, showcasing their potential in therapeutic applications.

Career Highlights

Throughout his career, Jennings has worked with prominent companies in the pharmaceutical industry, including Cephalon Australia Pty. Ltd. and Teva Pharmaceuticals Australia Pty Ltd. His work in these organizations has allowed him to collaborate with other experts in the field and contribute to innovative solutions in medicine.

Collaborations

Some of Jennings' notable coworkers include Anthony Gerard Doyle and Adam Clarke. Their collaborative efforts have further advanced the research and development of new therapeutic approaches.

Conclusion

Philip Anthony Jennings is a distinguished inventor whose work in antibody development has the potential to transform treatments for gastrointestinal and lung diseases. His contributions to biotechnology and collaboration with industry leaders highlight his commitment to innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…